Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
Clinical & Translational Immunology2022Vol. 11(2), pp. e1373–e1373
Citations Over TimeTop 10% of 2022 papers
Kevin Nishimoto, Taylor Barca, Aruna Azameera, Amani Makkouk, Jason M. Romero, Lu Bai, Mary M. Brodey, Jackie Kennedy‐Wilde, Hui Shao, Stephanie Papaioannou, Amy Doan, Cynthia Masri, Ngoc T. Hoang, Hayden Tessman, Vidhya Dhevi Ramanathan, Ana Giner‐Rubio, Frank J. Delfino, Kriti Sen Sharma, Kevin Bray, Matthew I. Hoopes, Daulet Satpayev, Ranjita Sengupta, Marissa Herrman, Stewart Abbot, Blake T. Aftab, Zili An, Swapna Panuganti, Sandra M. Hayes
Abstract
These preclinical data support the clinical evaluation of ADI-001, an allogeneic CD20 CAR+ Vδ1 γδ T cell, and a phase 1 study has been initiated in patients with B-cell malignancies (NCT04735471).
Related Papers
- → You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy(2020)109 cited
- Towards intraoperative identification of colorectal carcinoma using diffise reflectance spectroscopy : a comparison of in vivo and ex vivo measurements(2017)
- → Хірургічне лікування місцево-розповсюджених та рецидивних солідних пухлин черевної порожнини та заочеревинного простору з нефректомією ex vivo ex situ та аутотрансплантацією нирки(2018)
- → [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].(2018)
- → [Advances in Structural Designs of Chimeric Antigen Receptor T Cells--Review].(2022)